Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis by Wojtyniak, Jan-Georg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 109 NUMBER 1 | January 2021 201
Physiologically Based Precision Dosing 
Approach for Drug-Drug-Gene Interactions:  
A Simvastatin Network Analysis
Jan-Georg Wojtyniak1,2 , Dominik Selzer1, Matthias Schwab2,3,4 and Thorsten Lehr1,*
Drug-drug interactions (DDIs) and drug-gene interactions (DGIs) are well known mediators for adverse drug 
reactions (ADRs), which are among the leading causes of death in many countries. Because physiologically based 
pharmacokinetic (PBPK) modeling has demonstrated to be a valuable tool to improve pharmacotherapy affected by 
DDIs or DGIs, it might also be useful for precision dosing in extensive interaction network scenarios. The presented 
work proposes a novel approach to extend the prediction capabilities of PBPK modeling to complex drug-drug-
gene interaction (DDGI) scenarios. Here, a whole-body PBPK network of simvastatin was established, including 
three polymorphisms (SLCO1B1 (rs4149056), ABCG2 (rs2231142), and CYP3A5 (rs776746)) and four perpetrator 
drugs (clarithromycin, gemfibrozil, itraconazole, and rifampicin). Exhaustive network simulations were performed 
and ranked to optimize 10,368 DDGI scenarios based on an exposure marker cost function. The derived dose 
recommendations were translated in a digital decision support system, which is available at simva statin.preci 
siond osing.de. Although the network covers only a fraction of possible simvastatin DDGIs, it provides guidance 
on how PBPK modeling could be used to individualize pharmacotherapy in the future. Furthermore, the network 
model is easily extendable to cover additional DDGIs. Overall, the presented work is a first step toward a vision on 
comprehensive precision dosing based on PBPK models in daily clinical practice, where it could drastically reduce 
the risk of ADRs.
Adverse drug reactions (ADRs) are a burden to our health care 
and economic systems. The US Food and Drug Administration 
(FDA) assumes that annually >  2,216,000 serious ADRs in 
hospitalized patients lead to over 106,000 deaths in the United 
States—ranking them as the fourth leading cause of death.1,2 The 
associated costs are tremendous and are estimated to add up to 
US $200 billion per year.1 This situation is likely to become more 
acute as a result of ever-growing prescription use. According to 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Drug-drug interactions (DDIs), drug-gene interactions, and 
drug-drug-gene interactions (DDGIs) are well known triggers 
of adverse drug reactions that might be preventable by precision 
dosing. One example compound prone to DDGIs is simvastatin.
WHAT QUESTION DID THIS STUDY ADDRESS?
 How physiologically based pharmacokinetic (PBPK) mod-
eling can be utilized for model-informed precision dosing 
(MIPD) of complex DDGIs.
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 This study presents whole-body PBPK models for simvas-
tatin lactone and simvastatin acid, including variation of four 
pharmacogenes and was tested against four DDI perpetrator 
drugs and one DDI victim. In addition, the model was used to 
develop a digital decision support system based on dose recom-
mendations for 10,368 simulated interaction scenarios.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 The presented dose recommendations might help to better 
assess risks of simvastatin therapy in pharmacogenomic and 
polypharmacy context. Furthermore, the study highlights and 
guides how PBPK can help to bring MIPD into daily clinical 
practice.
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the Centers for Disease Control and Prevention, the proportion 
of Americans taking > 5 prescription drugs on a regular basis has 
almost tripled in the past 20 years.3
Drug-drug interactions (DDIs) and drug-gene interactions 
(DGIs) are the most common reasons for ADRs.2,4,5 Unfortunately, 
in current clinical practice DDIs and DGIs are considered sepa-
rate entities that are typically handled in a nonholistic fashion.4 
However, as shown recently, 19% of potentially clinically signifi-
cant interactions occur as a combination of DDIs and DGIs (drug-
drug-gene interaction (DDGIs)).4,5 Tackling DDIs, DGIs, or 
DDGIs using guidelines on dose adaption could reduce the num-
ber of ADRs substantially, because it is assumed that 80% of ADRs 
are dose-related and, hence, could be prevented.6,7 This concept 
can be summarized as precision dosing for DDIs and DGIs.8
The current approach of developing such guidelines would be 
the investigation of DDGIs in clinical trials analogous to presently 
conducted trials on DDIs and DGIs.8,9 Those studies are typically 
performed in healthy volunteers, in a homogenous study population 
and with a controlled treatment plan (Figure 1a).8 Consequently, 
they do not reflect the situation in multimorbid patients, affected 
by polypharmacy and genetic polymorphisms, which is the patient 
group most susceptible to ADRs (Figure 1b).1,8 Moreover, due 
to the combinatorial explosion of all possible DDGIs, exhaustive 
studies might not be feasible at all (Figure 1c).
Figure 1 Difference between a clinical study setting and a real-world post-approval setting. (a) The upper part shows the research situation 
in a clinical setting. A homogenous study population receives a defined treatment regimen in a standardized procedure. The subsequently 
obtained results are used for the development of therapy recommendations for the post-approval setting. The lower part depicts the real-
world postapproval setting with a higher variability in demographics, variant distribution, and a higher degree in polypharmacy compared 
with the clinical study population. As a result, as shown in (b) various possible DDGI scenarios are conceivable depending on the amount of 
concomitantly used perpetrator drugs and occurring polymorphisms. For the calculation it was assumed that each preparator has two DDI 
states (preparator is given or perpetrator is not given) and each clinically relevant polymorphism could have three independent phenotypes. 




polymorphism. The increase of possible DDGI scenarios is 
shown as a heatmap. The number of possible DDGI scenarios is shown on a log-scale. Some figure elements are taken from smart.servi 
er.com (CC BY 3.0). DDGI, drug-drug-gene interaction; DDI, drug-drug interaction. [Colour figure can be viewed at wileyonlinelibrary.com]
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To overcome this problem, a promising approach would be the 
application of whole-body physiologically based pharmacokinetic 
(PBPK) modeling.4 PBPK models hold the capability to predict 
the DDGI potential of drugs in silico and to develop alternative 
precision dosing regimens for patients.4 The reliability of this tech-
nique has already been demonstrated in several DDI and DGI 
studies and is acknowledged by regulatory agencies.10–12 However, 
although PBPK modeling has been accepted as a useful option to 
predict the extent of DDGIs, examples on how PBPK modeling 
can be used for model informed precision dosing (MIPD) are still 
scarce.12
Thus, the aim of this work was to illustrate the complexity of 
DDIs, DGIs, and DDGIs based on the example of simvastatin. 
Simvastatin was selected as it is among the most prescribed drugs in 
industrial nations and is highly susceptible to potentially life-threat-
ening ADRs due to its complex pharmacokinetics (PKs).13–18 
Moreover, this work should provide guidance for the development 
of an PBPK-based MIPD approach. Therefore, a comprehensive 
simvastatin DDGI PBPK network model was implemented to serve 
a web-based decision support system that offers quick and easy ac-
cess to optimized dose recommendations for individual patients.
METHODS
Software
PBPK model development was performed with PK-Sim and MoBi (version 
8 – Build 21) as part of the Open Systems Pharmacology Suite.19 Model pa-
rameter identification was accomplished using Monte-Carlo optimization. 
Local sensitivity analysis was also performed within PK-Sim. Published 
plasma concentration-time profiles were digitized using GetData Graph 
Digitizer (version 2.26.0.20, S. Fedorov).20 Graphics and statistical analy-
sis were produced and implemented using R (version 3.6.3).21
Simvastatin PBPK model building
The simvastatin model was developed in a stepwise procedure. In a first 
step, physicochemical parameters of simvastatin lactone (SL) and sim-
vastatin acid (SA) as well as information on absorption, distribution, 
metabolism, and excretion processes were extracted from literature. 
Subsequently, mean plasma concentration-time profiles of SL and SA 
after oral single dose and multiple dose administration were digitized 
from published studies and separated into training and test datasets for 
model development and evaluation, respectively. Model input parame-
ters, which were not available as PK-Sim reference values or that could 
not be informed from published literature values were optimized by fit-
ting the model to measured plasma concentration-time profiles from the 
training dataset. PBPK study simulations were built based on healthy 
individuals with the reported mean values for age, weight, height, and ge-
netic background, as stated in the corresponding study protocol, respec-
tively. If parameter information was lacking, a PK-Sim mean individual 
(healthy male European, 30 years of age, body weight of 73 kg, a height 
of 176 cm, and based on the International Commission on Radiological 
Protection database) with wild type genotype was substituted. For all 
simulated individuals, glomerular filtration and enterohepatic cycling 
was implemented. A detailed description of the model development pro-
cess, including information about digitized studies and model parame-
ters can be found in the Supplementary Material, chapter 2.
DGI implementation and DDI network development
DGI effects were implemented assuming a changed enzyme turnover 
number (kcat) compared with wild type. Here, the homozygous wild 
type kcat as well as kcat for homozygous polymorphic individuals were 
estimated during model training (see Supplementary Material, chapter 
1.1.2 and chapter 2.4).
A DDI network was built to further evaluate the performance of the 
developed model. Thus, previously developed models of clarithromycin, 
gemfibrozil, itraconazole, rifampicin, and midazolam were coupled with 
the simvastatin model.12,22,23 Population mean profiles as well as area 
under the curve (AUC) and peak plasma concentration (Cmax) values 
were predicted and compared against observed study data to evaluate the 
network quality.20
A detailed overview on the implementation of the DDI network, 
including relevant interaction parameters from in vitro experiments as 
well as the mathematical implementation of the drug interaction pro-
cesses, is provided in the Supplementary Material in chapter 1 and 
chapter 3.
PBPK network evaluation and sensitivity analysis
PBPK model evaluation was performed using different statistical and 
graphical evaluation techniques. Predicted plasma concentration-time 
profiles were compared with observed profiles. Moreover, goodness-
of-fit plots for predicted vs. observed plasma concentrations were ex-
amined. Mean relative deviation24 and median symmetric accuracy25 
were calculated for all differences between observed and predicted 
plasma concentrations. In addition, the performance was evaluated 
by comparison of the noncompartmental analysis parameters AUC 
from last dose to last observation and Cmax. AUC was computed using 
a linear-up log-down method. Geometric mean fold errors (GMFEs) 
were derived for differences between observed and predicted AUC and 
Cmax values. For DGI and DDI predictions, AUC effect ratios were 
compared, in which a deviation of the observed from the predicted ef-
fect ratio less than two times was considered sufficient. Finally, local 
sensitivity analysis of the final model to single parameter changes 
was calculated as relative changes of the AUC of one dosing inter-
val in steady-state conditions. A detailed overview of performance 
measurements and the local sensitivity analysis can be found in the 
Supplementary Material, chapter 1.4.
Dose optimization
Simvastatin dose optimization for several DDGI scenarios, including in-
dividual DDIs and DGIs was performed. As reference, plasma concentra-
tion-time profiles for SL and SA in a mean individual after administration 
of 5 mg up to 80 mg (5 mg steps) SL once daily for 7 days were simulated and 
SL and SA AUCs from the time of the last dose up to 24 hours postdose 
derived. In a second step, a DDGI matrix was set up covering every pos-
sible combination of the three polymorphisms SLCO1B1 (rs4149056), 
ABCG2 (rs2231142), and CYP3A5 (rs776746) and comedication with 
the four perpetrator drugs clarithromycin, itraconazole, gemfibrozil, and 
rifampicin. DDGI scenarios were simulated with administered SL doses 
according to the reference (7 days + 24 hours postdose) and reasonable 
perpetrator dosing regiments (see Table 1). For each simulation, SL and 
Table 1 Investigated perpetrator regimens
Perpetrator Half-life, monotherapy Regimen
Clarithromycin 3.3–4.9 hours 500 mg b.i.d.
Itraconazole ~ 24 hours 200 mg daily
Rifampicin 2.5 hours 600 mg daily 
concomitant with 
simvastatin
Rifampicin 2.5 hours 600 mg daily 17 hours 
after simvastatin 
dosing
Gemfibrozil 7.6 hours 600 mg b.i.d.
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SA AUCs were calculated. Following, relative AUC deviations of SL and 
SA from the reference values were computed for each DDGI scenario 
with an exposure marker cost function as shown in Eq. 1:
With Exposure Marker  =  Relative differences of SL and SA exposure 
per simvastatin dose as a cost function for dose optimization (the smaller 
the better), AUCSL−DDGIx = AUC for SL under DDGI condition, 
AUCSL− ref  = reference AUC for SL, AUCSA−DDGI = AUC for SA 
under DDGI condition, AUCSA− ref  = reference AUC for SA.
For each DDGI scenario, the exposure marker cost function was 
minimized to identify the simvastatin dose with the smallest exposure 
deviation (matching exposure). For different therapeutic dose levels of 
simvastatin (20  mg, 40  mg, and 60  mg) relative frequency of recom-
mended doses and the relationship between the number of DDGIs and 
the optimal dose level were analyzed. Moreover, a hierarchical Euclidian 
distance cluster analysis stratified against the DDIs and DGIs was per-
formed to identify patterns for generalized dose recommendations. 
Clustering was computed with complete linkage using the hclust func-
tion in R.
Results from the dose optimization were transferred into a DDS web ap-
plication implemented with the R package “shiny,” allowing users to easily 
filter simulation analysis tailored to DDGIs and simvastatin doses of interest.
RESULTS
Simvastatin PBPK model building and evaluation
We successfully developed a whole-body PBPK model of SL and 
SA. For placebo and DGI model development and evaluation 
mean data from 57 studies were extracted including 59 SL and 
57 SA plasma-concentration time profiles, which represent infor-
mation from 1,271 study participants. For DGI implementation, 
plasma-concentration time profiles or AUC and Cmax values for 
SLCO1B1 (rs4149056) c.521C/C, c.521T/C, c.521T/T, ABCB1 
(rs1128503 rs2032582 and rs1045642) c.1236T-c.2677T-
c.3435T, c.1236C-c.2677G-c.3435C, ABCG2 (rs2231142) 
c.421A/A, c.421C/A, c.421C/C, and CYP3A5 (rs776746) 
CYP3A5*3/*3, CYP3A5*3/*1, CYP3A5*1/*1 were used for 
model development and optimization. System-dependent pa-
rameters like reference concentrations and enzyme expression 
profiles were taken from the PK-Sim database or extracted from 
literature as described in Supplementary Material, chapter 1.3. 
Doses available for model development and evaluation ranged 
from 10 mg to 80 mg simvastatin after single and multiple doses.
Extensive model evaluations, as described in the Supplementary 
Material, chapter 2.3, revealed good model performance for pla-
cebo PK profiles. Mean ratios predicted vs. observed AUCs were 
1 for SL and 0.9 for SA. Mean predicted vs. observed Cmax ratios 
were 0.9 and 0.8 for SL and SA, respectively. GMFE values were 
1.3 for SL AUC, 1.5 for SL Cmax, 1.5 for SA AUC, and 1.7 for SA 
Cmax, respectively.
DGI model evaluation
The model was capable to precisely describe and predict the DGI 
profiles in the training and test datasets. The average AUC ratio 
was 1.0 for SL and 0.7 for SA, whereas the mean Cmax ratio was 
0.8 for SL and 0.6 for SA. For DGIs the GMFE values were 1.3 
for SL AUC and 1.4 for SL Cmax, 1.8 for SA AUC, and 2.2 for SA 
Cmax, respectively (see Supplementary Material, chapter 2.4.6). 
Figure 2a shows an example prediction of SA for SLCO1B1 
(rs4149056) c.521C/C and c.521T/T genotype.
DDI network development
A DDI network was built by coupling models for clarithro-
mycin, gemfibrozil, itraconazole, rifampicin, and midazolam 
with the newly derived simvastatin model (see Supplementary 
Material, chapter 3). Figure 2b shows an example prediction 
of SL under clarithromycin cotreatment. Mean predicted vs. ob-
served AUC ratios for SL, SA, and midazolam were 1.2, 1.5, and 
0.9, respectively. Average predicted vs. observed Cmax ratios for 
SL, SA, and midazolam were 0.9, 1.1, and 1, respectively. GMFE 
values were 1.3 for both SL AUC and Cmax, 1.7 and 1.8 for SA 
AUC and Cmax, as well as 1.1 for both midazolam AUC and 
Cmax.
Moreover, predicted DDI and DGI effect ratios were in good 
agreement with observed effect ratios, as shown in Figure 2c. 
Overall, only 1 of 18 AUC effect ratios for SL and 1 of 14 AUC 
effect ratios for SA showed a deviation from the observed effect 
ratio greater than twofold. Figure 3 summarizes the metabolic 
and transportation processes involved in the DDI network and 
visualizes the relationships between the included compounds and 
processes.
Dose optimization
For each simvastatin therapeutic dose (5 to 80 mg in 5 mg steps) 
648 DDGIs were optimized, which led to a total of 10,368 DDGI 
dose recommendations derived from the exposure marker cost 
function as described in Eq. 1. Cluster analysis revealed that clus-
ter groups differ vastly with several subclusters and no observable 
pattern (Figure 4a). Thus, no generally applicable rule could be 
established on how to dose simvastatin.
Descriptive statistics revealed that for 13% (60 mg simvastatin 
therapeutic dose) to 25% (20 mg simvastatin therapeutic dose) of 
the investigated DDGI scenarios no alternative simvastatin dose 
could be found. Median optimal dose levels over all investigated 
DDGIs were 5 mg, 10 mg, and 20 mg for simvastatin therapeutic 
doses of 20  mg, 40  mg, and 60  mg, respectively. Analyses of the 
number of DDGIs against the optimal doses revealed a trend for all 
therapeutic dose levels: a greater number of DDGIs leads toward a 
lower optimal dose. For a therapeutic dose level of 40 mg, results 
are visualized in Figure 4a (cluster analysis), Figure 4b (relative 
frequency of optimal doses), and Figure 4c (number of DDGIs 
against optimal dose values).
DDGI network simulations were processed and transferred 
into a web-based interactive decision support system, which can 
be accessed at simva statin.preci siond osing.de. The system al-
lows users to investigate simvastatin DDGI situations of interest 
and explore different scenarios. Here, the user can select a given 
simvastatin dose, the active comedication, and the SLCO1B1, 
ABCG2, and CYP3A5 genotype. Then, the application presents 
the optimization results, including recommended dose com-
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of SL and SA exposures for the placebo situation, the investi-
gated DDGI situation, and the situation after dose optimiza-
tion. Figure 5 depicts case examples analyzed with the support 
system.
DISCUSSION
PBPK modeling is increasingly applied during preclinical and 
clinical development allowing prospective prediction of drug 
exposure for various scenarios. Investigation of DDIs for reg-
ulatory labeling recommendations and problems regarding 
organ impairment, drug absorption, and pediatric starting dose 
selection demonstrated the usefulness of this class of mecha-
nistical models in the past.26 Because DDIs and DGIs can be 
considered as major drivers of ADRs2,4,5 the application of 
PBPK-based MIPD to reduce the incidence of ADRs seems 
sensible. However, efforts toward the application of physiolog-
ically based models for MIPD are still scarce.12 In this work, 
we investigated the adaption of PBPK modeling approaches 
for precision dosing regarding DDGI-sensible compounds in 
complex interaction networks and the integration of finding 
into a decision support system.
Current techniques to address MIPD typically include Bayesian 
adaptive control methods.8,27 However, these approaches are lim-
ited to interactions, which are already studied and implemented in 
the model.8 An extension with other, clinically untested perpetrator 
or victim drugs or further genetic polymorphisms, is challenging or 
even impossible. In contrast, PBPK models are well-suited to tackle 
this limitation and are emphasized by regulatory agencies to inves-
tigate new, untested scenarios.4,8,10–12 At the moment, most whole-
body PBPK models purely account for interindividual variability 
by adapting the physiology of the underlying virtual patient. Hence, 
the estimation of individual parameters, as it is accomplished in 
Bayesian methods, is hardly feasible. Consequently, future devel-
opments should focus on connecting approaches like maximum a 
posteriori estimation to the realm of PBPK modeling in order to 
allow PBPK Bayesian techniques to come within reach, combining 
the best from both worlds. As an application example, such mod-
els could use the interindividual variability of a metabolic enzyme 
Figure 2 Example profiles and model evaluation plots for the developed simvastatin PBPK DDGI network. (a) Example profiles of the observed 
vs. predicted simvastatin acid plasma concentration-time profiles for SLCO1B1 (rs4149056) c.521C/C, and c.521T/T genotypes.54 (b) 
Example profiles of the predicted vs. observed simvastatin lactone plasma concentration-time profiles with and without clarithromycin co-
treatment.55 In a and b dots are observed mean values extracted from literature. Error bars display the observed SDs. Solid lines show the 
predicted median profile of 100 simulated individuals. Shaded area depicts the predicted 90% confidence interval. (c) Depicts the observed 
vs. predicted dose normalized AUC effect ratios (dose normalized AUC under DDI/DGI conditions divided by dose normalized AUC under 
placebo conditions). Solid lines show the line of identity as well as the twofold deviations. Dotted lines are the quality limits as proposed 
by Guest et al.56 AUC, area under the curve; DDGI, drug-drug-gene interaction; DDI, drug-drug interaction; PBPK, physiologicallybased 
pharmacokinetic. [Colour figure can be viewed at wileyonlinelibrary.com]
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and, based on the measured individual plasma concentration of a 
harmless reference substance, predict the optimal treatment regime 
for another compound that is metabolized by this very enzyme. 
This will require further technical development, the availability of 
sufficient individual data, and additional physiological knowledge, 
but could consequently improve the precision of the PBPK-based 
MIPD approach. Fortunately, the continuous research efforts, as 
for example, shown by the open systems pharmacology community, 
Figure 3 Relationships between the PK pathways of the compounds included in the presented DDGI network. For the six different drugs 
simvastatin, itraconazole, rifampicin, gemfibrozil, clarithromycin, and midazolam metabolic, inhibitory and inductive effects are shown as lines. 
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constantly extend the library of available PBPK models and model 
features.28 This progressive trend is encouraging that current 
knowledge and technical gaps can steadily be narrowed.
We demonstrated the applicability of physiologically based 
precision dosing using the example of simvastatin. Because it is 
among the drugs most frequently involved in major interactions, 
Figure 4 Results from the dose optimization analysis. (a) Heatmap of the performed cluster analysis. Investigated DGIs are shown on the 
x-axis, whereas DDIs are listed on the y-axis. A color-coding as described on the right side of the plot depicts the optimal doses for each DDGI 
combination. Cluster analysis results are shown as dendrograms on the right and top site of the heatmap. Furthermore, simvastatin treatment 
without additional DDI-partner, single cotreatment with itraconazole or clarithromycin and the DGI situation for SLCO1B1 (rs4149056) c.521C/C 
are highlighted with rectangles. (b) Shows the relative distribution of optimal doses for simvastatin. Solid lines depict the therapeutic dose. (c) 
Boxplots visualizing the number of DDGIs against the optimal simvastatin doses. All boxplots show the following descriptive statistics: The median 
value, the interquartile range, and the 1.5-fold interquartile range. All analyzes are shown for a therapeutic dose level of 40 mg simvastatin. DDGI, 
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simvastatin is a perfect candidate to showcase the feasibility of 
physiologically based dose recommendations for known DGIs 
and comedication with frequently used DDI partners.5 For sim-
vastatin, only two whole-body or semimechanistic PBPK models 
are described in the literature yet.29,30 Despite good predictive per-
formance for the area of application, they typically focused on a 
single polymorphism (e.g., SLCO1B1 (rs4149056)) and one DDI 
CYP3A4 inhibition effect. In contrast, our work vastly broadens 
the area of application by the successful development of a newly 
built whole-body simvastatin PBPK model covering multiple 
crucial PK processes. Subsequently, the model was connected to 
a comprehensive DDGI network to extensively study and simu-
late complex DDGI scenarios. The final model covered four im-
portant polymorphisms in the ABCB1, SLCO1B1, ABCG2, and 
CYP3A5 genes20,31–35 relevant for simvastatin’s PK and was tested 
using previously developed and evaluated models for the perpe-
trators itraconazole, rifampicin, clarithromycin, gemfibrozil, and 
the victim midazolam.10–12,23 The simvastatin network showed 
overall good descriptive and predictive performance and was hence 
used for further dose optimization analysis. Despite good perfor-
mance, the model has some limitations, which are primarily caused 
by insufficient or lacking model input data. For example, for all 
studies where no information about the genotype was provided, 
homozygous wild type genotypes were assumed. Fortunately, the 
prediction of included placebo profiles with unknown genotype 
showed that this assumption is sufficient to achieve good model 
accuracy. Information about the known polymorphism in ABCB1 
was rare and could only be included in the model training dataset 
and not for testing. Moreover, for some simvastatin PK pathways 
no data regarding their significance or activity could be gathered 
(see Supplementary Material, chapter 2). Those pathways and 
associated processes could either not be included in the model 
or their affinity (Km) or activity (kcat) values had to be estimated. 
Here, additional in vitro studies could help to fill this knowledge 
gaps in the future and, subsequently, further improve the model 
quality.36
Although precision dosing is considered a public health need, 
the amount and availability of recommendations for adjustments 
in case of DDGIs, including DDIs and DGIs, are lagging behind. 
For simvastatin, 5 pharmacogenes are listed on pharm gkb.org 
as level 2 variants, which equals at least moderate evidence for a 
significant influence on the pharmacotherapy.15 Yet, only for one 
polymorphism in SLCO1B1 (rs4149056) recommendations on 
how to adapt the dose are on hand.15,37,38 For the poor function 
SLCO1B1 genotype (c.521C/C) low dosing, prescription of an 
alternative statin or routine creatine kinase surveillance is typically 
Figure 5 Case examples analyzed with the developed decision support system. Therapeutic simvastatin dose was 40 mg and SL and SA 
exposure deviation were equally weighted. From left to right, different recommendations for action are given depending on the deviation 
between the optimal dose under DDGI condition compared with the therapeutic dose. DDGI, drug-drug-gene interaction; SA, simvastatin acid; 
SL, simvastatin lactone. [Colour figure can be viewed at wileyonlinelibrary.com]
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recommended.37,38 Our developed model-based dose recommen-
dations agree on the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) guideline by also recommending an alter-
native drug for the SLCO1B1 c.521C/C polymorphism (see 
Figure 5).37,38 The FDA drug label of simvastatin (Zocor) con-
traindicates the concomitant use of strong CYP3A4 inhibitors 
like itraconazole or clarithromycin.39 This is also reflected by 
the presented PBPK DDGI network as shown in Figure 4a (red 
highlighting rectangles) for single clarithromycin or itraconazole 
cotreatment. Except for DDGIs with some CYP3A5 activity 
(*1/*1 or *1/*3), the model always predicts that no optimal sim-
vastatin dose could be found (optimal dose = 0 mg). This is not 
surprising, because the originally published clarithromycin and 
itraconazole models did not include CYP3A5 inhibition (see 
Supplementary Material, chapter 3).10,23 Although there are 
hints of CYP3A5 inhibition by itraconazole or clarithromycin in 
past studies, information available were too sparse to include this 
process in the models.40,41 This lack of information is most likely 
due to the fact that the CYP3A5*3/*3 nonexpressor genotype is 
the major genotype in many populations without recent African 
ancestry. Although only 10–25% of Europeans have detectable lev-
els of hepatic CYP3A5, this rate increases to 55–95% in African 
Americans.42–44 For scenarios were CYP3A5 shows activity, it 
partly replaces the metabolic clearance of CYP3A4 in the net-
work. Whether this holds true and a DDGI with clarithromycin 
or itraconazole and CYP3A5 only leads to a slightly increased SL 
exposure should be further investigated.
Apart from individual DDIs or DGIs, there is currently no rec-
ommendation for simvastatin DDGIs available.39 Unfortunately, 
this is not only the case for simvastatin but reflects the situation 
for the majority of available drugs.4 The standard to overcome 
this deficiency are clinical trials. However, due to the combinato-
rial explosion of possibilities for complex DDGIs exhaustive in-
vestigation via clinical studies is not feasible.4,9 As shown in the 
performed cluster analysis (Figure 4a) for complicated DDGIs, 
no generally valid rule or therapy recommendation can be given, 
making it indeed necessary to investigate DDGIs on an individual 
level. With the rapid increase in efficiency and availability of com-
putational resources (e.g., via cloud computing) the application of 
rich PBPK DDGI networks for MIPD, as shown in the presented 
study, seems feasible. Yet, clinical studies evaluating more complex 
situations like DDGIs are urgently needed to challenge, refine, and 
validate MIPD predictions.12
Even though the presented work exceeds the number of cur-
rently available dose recommendations by far, it still only applies 
to a small fraction of possible simvastatin DDGIs. Furthermore, 
it should be noted that dose optimization was only performed 
for matching exposure and not linked with a pharmacodynamic 
(PD) model connecting SL and SA exposure with drug efficacy 
like change in LDL levels or drug toxicity.43,45,46 Such a PBPK/
PD MIPD decision support system could enable clinicians to 
individually balance therapy risks and chances.47,48 However, as 
recent investigations have shown, those models should also regard 
the exposure of SL, which had not been recognized for a long 
time.49 Results from Tahaa et al. indicate that SL could be more 
relevant for drug’s toxicity, whereas SA could be more important 
for efficacy.49 For this reason, the exposure marker cost function 
used for dose optimization was derived from both exposure devi-
ations in order to account for SL exposure deviations as well. By 
further implementing a weighting factor, the clinician is still free 
to set the influence for both species individually. Nevertheless, 
this highlights that further models and model extensions are 
required to enlarge the current network. Fortunately, the estab-
lished PBPK network shows enough flexibility to be extended as 
soon as more models for PD effects, perpetrator, or victim com-
pounds are available.10–12,23 Such models can then easily be linked 
with the current network and subsequently be used for further 
optimizations.10–12,23
The simulation analyses for DDGI scenarios were simulated for 
7 days + 24 hours postdose. Although, for single drug treatment, 
this simulation time should be sufficient to reach PK steady-state 
conditions for all compounds investigated,50–53 this assumption 
might not hold true for complex DDGI scenarios. However, as a 
priori effect estimations of complex DDGI scenarios on drug half-
lives is not feasible, this should be considered for any follow-up 
simulation analysis.
As stated by Gonzalez and coworkers, a precision dosing strategy 
for clinical practice does not only rely on the development of pre-
dictive dosing models, but also on the integration into a decision 
support system accessible by the physician.8 Thus, we provide an ex-
emplary implementation of such a system for simvastatin to demon-
strate ease of use for modeling nonexperts via a web-based solution.
In conclusion, a novel physiologically based precision dosing 
approach was successfully developed to study complex DDGI 
network scenarios for the model drug simvastatin. Findings from 
extensive cluster analysis of various DDGIs showed no generalized 
pattern for dose adjustments suggesting the need for individualized 
MIPD approaches to ensure effectiveness of therapy and prevention 
of severe ADRs. It could be demonstrated that adaption of whole-
body PBPK modeling for MIPD allows the flexible extension and 
requalification of already established interaction networks more 
easily and with greater confidence for unknown scenarios than al-
ready established tooling for MIPD. Future developments should 
focus on enhancing the capabilities of PBPK modeling by inte-
gration of Bayesian adaptive control mechanisms like maximum 
a posteriori estimation allowing more fine-grained personalized 
readjustment for DDI-sensible and DGI-sensible drugs. Efforts for 
open access model deployment should be promoted for more wide-
spread utilization. Besides open access to models, the integration 
with easy to use decision support systems is crucial to allow the 
adaption into clinical practice. Thus, for further use, all simvastatin 
DDGI network model files are publicly available (https://github.
com/Clini cal-Pharm acy-Saarl and-Unive rsity) and the physiologi-
cally based precision dosing decision support system is deployed 
for open access at simva statin.preci siond osing.de.
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